We face three major challenges that need concerted efforts of society and the R&D community as a whole. Given the multitude of the challenges, these efforts require a fundamental paradigm shift in drug development.
We focus on chronic inflammatory diseases and cancer.
We engage in the global fight against COVID-19.
Most inflammatory disease targets and many cancers, dominated by protein-protein interactions, are among the most difficult ones to drug.
Another challenge is that limited druggability of disease leads to “compromises” in target selection, potentially ignoring the targets most suitable for treatment. This includes the focus on one target rather than evaluating multi-target pathways.
Additionally, conventional methods limit the opportunities to discover and develop oral therapies leaving the field unnecessarily to complex and costly therapies like antibodies.
